LNTHLantheus Holdings, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 11% a year, expectations look modest.
In its normal range: P/E 24.3 vs a 21.2 median over 34 quarters (+15% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What LNTH's price assumes
Lantheus Holdings, Inc. trades at 24.3× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · 1.23× the median: the market pays up for this one
- Price / sales
- 4.56
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 5.5%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +4.5%
Growth the price implies · The price pays for +4.5% free cash flow growth a year for a decade; revenue has grown +11% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.41
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 23.4
- EV / salestoday's price, trailing year to Jun 30, 2026
- 4.55
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $388M
- Market capitalisation
- $7.10B
- 3-year revenue growth
- +11%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $54.57 |
| Its own P/E history, median | $87.38 |
| Its own P/E history, upper quartile | $117.34 |
| 52-week range | $50.11 – $109.01 |
| Today | $100.15 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #5 of 41 by RyuScore